Track market-moving stories before they get noisy

Brown-Forman Corporation reported stable earnings in Q4. The performance is good when considering significant sector pressure in developed markets. Successful product launches, distribution changes, and better growth in emerging markets continue to drive Brown-Forman's relative strength. The FY2027 outlook isn't as good. Slowing alcohol consumption weighs on the sales outlook, and Brown-Forman will start to bottle more expensive inventory from early 2020s.

WSFS Financial (WSFS - Free Report) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.

The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.

Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system comes in handy because of the power of a changing earnings picture in determining near-term stock price movements.

As such, the Zacks rating upgrade for WSFS is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, has proven to be strongly correlated with the near-term price movement of its stock. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For WSFS, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsEmpirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, so it could be truly rewarding if such revisions are tracked for making an investment decision. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for WSFSFor the fiscal year ending December 2026, this bank holding company is expected to earn $5.78 per share, which is unchanged compared with the year-ago reported number.

Analysts have been steadily raising their estimates for WSFS. Over the past three months, the Zacks Consensus Estimate for the company has increased 11.5%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of WSFS to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

Great Southern Bancorp (NASDAQ: GSBC - Get Free Report) and WSFS Financial (NASDAQ: WSFS - Get Free Report) are both finance companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, analyst recommendations, risk, institutional ownership and dividends. Analyst Ratings This is a summary of

Posted by Defense World Staff on Apr 6th, 2026

Aberdeen Group plc trimmed its holdings in WSFS Financial Corporation (NASDAQ:WSFS – Free Report) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 383,212 shares of the bank’s stock after selling 18,517 shares during the period. Aberdeen Group plc owned 0.70% of WSFS Financial worth $21,169,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Bryn Mawr Trust Advisors LLC purchased a new stake in WSFS Financial in the 3rd quarter valued at approximately $1,051,000. Tudor Investment Corp ET AL purchased a new position in WSFS Financial during the third quarter worth $1,153,000. Cooke & Bieler LP raised its holdings in shares of WSFS Financial by 15.5% in the third quarter. Cooke & Bieler LP now owns 1,031,956 shares of the bank’s stock worth $55,653,000 after acquiring an additional 138,220 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of WSFS Financial by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 1,544,508 shares of the bank’s stock worth $83,295,000 after acquiring an additional 33,398 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB lifted its position in shares of WSFS Financial by 46.5% in the third quarter. Wilmington Savings Fund Society FSB now owns 89,669 shares of the bank’s stock valued at $4,836,000 after acquiring an additional 28,471 shares in the last quarter. 88.49% of the stock is currently owned by hedge funds and other institutional investors.

WSFS Financial Stock Performance NASDAQ:WSFS opened at $66.30 on Monday. The business’s 50-day moving average is $65.16 and its two-hundred day moving average is $58.68. The firm has a market capitalization of $3.50 billion, a PE ratio of 13.00 and a beta of 0.75. WSFS Financial Corporation has a 12 month low of $42.44 and a 12 month high of $71.32. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.84 and a quick ratio of 0.84.

WSFS Financial (NASDAQ:WSFS – Get Free Report) last issued its earnings results on Monday, January 26th. The bank reported $1.43 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.17. WSFS Financial had a return on equity of 10.89% and a net margin of 21.14%.The company had revenue of $90.08 million during the quarter, compared to the consensus estimate of $267.36 million. During the same quarter in the prior year, the business earned $1.11 earnings per share. The company’s revenue was up 4.0% compared to the same quarter last year. Research analysts predict that WSFS Financial Corporation will post 4.47 earnings per share for the current fiscal year.

WSFS Financial Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Friday, February 13th were paid a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Friday, February 13th. WSFS Financial’s dividend payout ratio is 13.33%.

Wall Street Analyst Weigh In A number of analysts recently issued reports on the stock. TD Cowen restated a “buy” rating on shares of WSFS Financial in a research report on Wednesday, January 28th. Zacks Research downgraded WSFS Financial from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Brean Capital started coverage on shares of WSFS Financial in a research note on Tuesday, March 10th. They set a “buy” rating and a $74.50 price objective for the company. DA Davidson initiated coverage on shares of WSFS Financial in a report on Wednesday, February 25th. They set a “neutral” rating and a $74.00 price objective on the stock. Finally, Stephens reiterated an “overweight” rating and issued a $71.00 price target (up from $66.00) on shares of WSFS Financial in a report on Wednesday, January 28th. Four equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $71.42.

Get Our Latest Stock Analysis on WSFS Financial

Insiders Place Their Bets In other WSFS Financial news, EVP Arthur J. Bacci sold 2,005 shares of the company’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $70.51, for a total transaction of $141,372.55. Following the sale, the executive vice president owned 26,366 shares in the company, valued at $1,859,066.66. This represents a 7.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Shari Kruzinski sold 1,000 shares of the stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $70.10, for a total value of $70,100.00. Following the transaction, the executive vice president directly owned 14,740 shares in the company, valued at approximately $1,033,274. This represents a 6.35% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 3,455 shares of company stock valued at $242,923 in the last ninety days. Corporate insiders own 1.10% of the company’s stock.

About WSFS Financial (Free Report)

WSFS Financial Corporation is the bank holding company for WSFS Bank, a regional financial institution headquartered in Wilmington, Delaware. The company traces its roots to the Safe Deposit & Trust Company, founded in 1832, and formally organized as WSFS Financial in the mid-1980s. Over its long history, WSFS has grown through a combination of organic expansion and selective acquisitions to serve a broad base of individual, commercial and institutional clients.

WSFS Bank offers a full suite of banking and financial services, including retail and commercial deposit accounts, commercial and industrial lending, real estate financing, and treasury management solutions.

See Also Five stocks we like better than WSFS Financial

Receive News & Ratings for WSFS Financial Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WSFS Financial and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAberdeen Group plc Has $21.38 Million Stock Position in Weyerhaeuser Company $WY

NEXT HEADLINE »Aberdeen Group plc Acquires 30,723 Shares of Amdocs Limited $DOX

WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation (Nasdaq: WSFS), the parent company of WSFS Bank, expects to report its first quarter earnings at the end of business on Thursday, April 23, 2026. Management will conduct a conference call to review this information at 1:00 p.m. Eastern Time (ET) on Friday, April 24, 2026.

Interested parties can register in advance here or access the conference call live at investors.wsfsbank.com. Earnings release and supplemental materials will be available prior to the start of the event via the Investor Relations section of the Company’s website, and participants are advised to log on at least 15 minutes prior to the broadcast.

For those who cannot access the live conference call, a replay will be accessible shortly after the event concludes through the links above.

About WSFS Financial Corporation

WSFS Financial Corporation is a multibillion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally headquartered bank and wealth management franchise in the Greater Philadelphia and Delaware region. As of December 31, 2025, WSFS Financial Corporation had $21.3 billion in assets on its balance sheet and $97.4 billion in assets under management and administration. WSFS operates from 113 offices, 87 of which are banking offices, located in Pennsylvania (58), Delaware (37), New Jersey (14), Florida (2), Nevada (1) and Virginia (1) and provides comprehensive financial services including commercial banking, consumer banking, treasury management, and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Bryn Mawr Trust Advisors, LLC, Bryn Mawr Trust®, The Bryn Mawr Trust Company of Delaware, Cash Connect®, NewLane Finance®, WSFS Wealth® Management, LLC, WSFS Institutional Services®, and WSFS Mortgage®. Serving the Greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit www.wsfsbank.com.

WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation (Nasdaq: WSFS), the parent company of WSFS Bank, announced today it has entered into a long-term lease for its office located at 1818 Market Street. This renewal ensures the company remains a fixture of the Philadelphia skyline and a prominent member of the local business community.

“This lease renewal underscores our unwavering commitment to Philadelphia, a city that has been integral to our growth and success as an organization,” said Rodger Levenson, WSFS Chairman, President, and CEO. “Philadelphia is not just a key market for WSFS; it’s a vibrant community where we are proud to be an employer of choice, fostering opportunities for our Associates and contributing to the city’s economic vitality.”

The building, also known as WSFS Bank Place, has been occupied by WSFS since 2019 and now houses more than 250 Associates. WSFS further enhanced its presence at Bank Place in 2024 with the opening of a WSFS banking office, full-service ATM, and accompanying Wiss Fiss Lounge.

“This renewed investment in our Center City office reflects our dedication to collaboration, innovation, and delivering exceptional service to our Philadelphia-based clients and communities for years to come,” said Levenson.

About WSFS Financial Corporation

WSFS Financial Corporation is a multibillion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally headquartered bank and wealth management franchise in the Greater Philadelphia and Delaware region. As of December 31, 2025, WSFS Financial Corporation had $21.3 billion in assets on its balance sheet and $97.4 billion in assets under management and administration. WSFS operates from 113 offices, 87 of which are banking offices, located in Pennsylvania (58), Delaware (37), New Jersey (14), Florida (2), Nevada (1) and Virginia (1) and provides comprehensive financial services including commercial banking, consumer banking, treasury management, and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Bryn Mawr Trust Advisors, LLC, Bryn Mawr Trust®, The Bryn Mawr Trust Company of Delaware, Cash Connect®, NewLane Finance®, WSFS Wealth® Management, LLC, WSFS Institutional Services®, and WSFS Mortgage®. Serving the Greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit www.wsfsbank.com.

WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation (Nasdaq: WSFS), the parent company of WSFS Bank, today announced its financial results for the first quarter of 2026.

Selected financial results and metrics are as follows:

(Dollars in millions, except per share data)

1Q 2026

4Q 2025

1Q 2025

Net interest income

$

185.1

$

187.4

$

175.2

Fee revenue

90.1

84.5

80.9

Total net revenue

275.3

271.9

256.1

(Recovery of) provision for credit losses

(2.0

)

12.7

17.4

Noninterest expense

162.8

162.0

151.8

Net income attributable to WSFS

86.8

72.7

65.9

Pre-provision net revenue (PPNR)(1)

112.5

109.9

104.3

Earnings per share (EPS) (diluted)

1.64

1.34

1.12

Return on average assets (ROA) (a)

1.61

%

1.33

%

1.29

%

Return on average equity (ROE) (a)

12.7

10.5

10.1

Fee revenue as % of total net revenue

32.7

31.0

31.5

Efficiency ratio

59.0

59.5

59.2

See “Notes”

GAAP results for the periods shown include items that are excluded from core results. Below is a summary of the financial effects of these items. In 1Q 2026, these items include restructuring expenses related to a loss on a property sale and a write-down of held-for-sale real estate. For additional detail, refer to the Non-GAAP Reconciliation in the back of this earnings release.

1Q 2026

4Q 2025

1Q 2025

(Dollars in millions, except per share data)

Total (pre-tax)

Per share (pre-tax)

Total (pre-tax)

Per share (pre-tax)

Total (pre-tax)

Per share (pre-tax)

Fee revenue

$

—

$

—

$

(5.6

)

$

(0.10

)

$

—

$

—

Noninterest expense

2.9

0.05

1.1

0.02

0.3

0.01

Income tax impacts

(0.6

)

(0.01

)

(1.6

)

(0.03

)

(0.1

)

—

(1) As used in this press release, PPNR is a non-GAAP financial measure that adjusts net income determined in accordance with GAAP to exclude the impacts of (i) income tax provision and (ii) (recovery of) provision for credit losses. For a reconciliation of this and other non-GAAP financial measures to their most directly comparable GAAP measures, see "Non-GAAP Reconciliation" at the end of the press release.

CEO Commentary and Highlights

Rodger Levenson, Chairman, CEO and President, said, "WSFS performed very well in the first quarter as reflected by a 49% year-over-year increase in core EPS(2). Our results included robust deposit growth, solid C&I loan fundings, and strong performance in our Wealth and Trust segment, which delivered double-digit year-over-year fee revenue growth. Additionally, we continued to execute our capital return framework through dividends and share repurchases. We look forward to building on this momentum as we optimize ongoing franchise investments and grow market share across our diversified businesses."

Overall highlights included:

Core EPS of $1.68 increased 17% and core ROA(2) of 1.65% increased 23bps compared to 4Q 2025. Excluding a previously disclosed $15.7 million loan recovery, core EPS(2) was $1.45 and core ROA(2) was 1.43%. Wealth and Trust continued to deliver double-digit fee growth, increasing 25% year-over-year. WSFS Institutional Services® increased 46% and The Bryn Mawr Trust Company of Delaware (BMT of DE) increased 27%. Client deposits grew 5% quarter-over-quarter with strong noninterest demand growth of 14% primarily driven by Trust and Commercial. C&I loans grew 2% quarter-over-quarter driven by strong fundings. The Board approved an 18% increase in the quarterly cash dividend to $0.20 per share, along with an additional share repurchase authorization of 15% of our outstanding shares as of March 31, 2026. Repurchased $85.0 million of common stock (2.5% of outstanding shares(3)) and paid quarterly dividends of $9.0 million, for a total capital return of $94.0 million. First Quarter 2026 Discussion of Financial Results

Balance Sheet

The following table summarizes loan and lease balances and composition at March 31, 2026 compared to December 31, 2025 and March 31, 2025:

Loans and Leases

(Dollars in millions)

March 31, 2026

December 31, 2025

March 31, 2025

Commercial & industrial (C&I)(4)

$

4,849

37

%

$

4,766

36

%

$

4,651

36

%

Commercial mortgage

3,882

30

3,916

30

3,982

31

Construction

1,034

7

1,024

7

869

6

Commercial small business leases

588

4

603

5

636

5

Total commercial loans and leases

10,353

78

10,309

78

10,138

78

Residential mortgage

1,127

9

1,120

9

992

8

Consumer

1,854

14

1,894

14

2,033

16

Gross loans and leases

13,334

101

%

13,323

101

%

13,163

102

%

Allowance for Credit Losses (ACL)

(180

)

(1

)

(179

)

(1

)

(188

)

(2

)

Net loans and leases

$

13,154

100

%

$

13,144

100

%

$

12,975

100

%

At March 31, 2026, WSFS’ gross loan and lease portfolio increased $10.6 million, or less than 1%, when compared with December 31, 2025. C&I fundings remained strong, resulting in growth of 2% (not annualized), which included 4% growth in Small Business Banking(5). This growth reflects our continued investment in talent and product offerings, enhancing our ability to win market share and more effectively compete for a broader set of clients. Despite seasonal trends, residential mortgage and home equity generated strong originations and delivered over 1% combined growth. The strong funding momentum was partially offset by elevated payoff and paydown activity in commercial mortgage and residential mortgage as well as the continued runoff of Spring EQ loans.

Gross loans and leases at March 31, 2026 increased 1% when compared with March 31, 2025. Excluding the impacts from the sale of the Upstart portfolio and runoff of Spring EQ, gross loans and leases increased 4%. C&I fundings more than doubled year-over-year, resulting in growth of 4%, while construction loans (19%), residential mortgage (14%), and WSFS-originated consumer loans (15%) also grew. These increases were partially offset by declines in commercial mortgage (3%) and commercial small business leases (8%).

The following table summarizes client deposit balances and composition at March 31, 2026 compared to December 31, 2025 and March 31, 2025:

Client Deposits

(Dollars in millions)

March 31, 2026

December 31, 2025

March 31, 2025

Noninterest demand

$

6,372

34

%

$

5,577

32

%

$

4,947

29

%

Interest-bearing demand

2,848

15

2,884

16

2,882

17

Savings

1,418

8

1,410

8

1,463

9

Money market

5,909

33

5,762

33

5,487

33

Total core deposits

16,547

90

15,633

89

14,779

88

Time deposits

1,921

10

2,009

11

2,100

12

Total client deposits

$

18,468

100

%

$

17,642

100

%

$

16,879

100

%

Total client deposits increased $826.0 million, or 5% (not annualized), when compared with December 31, 2025. Noninterest demand increased 14%, driven by growth in Trust and Commercial, and comprises 34% of total client deposits. Money market grew 3%, while time deposits decreased 4%. End of period deposit balances reflect elevated activity by clients within Trust and Commercial. While some of these transactional deposits are short-term, we continue to see strong deposit growth across our franchise.

Total client deposits increased $1.6 billion, or 9% from March 31, 2025. Noninterest demand grew 29%, driven by Trust and Commercial. Money market grew 8%, driven by Consumer, Trust, and Private Wealth Management, while time deposits decreased 8% as we continued to manage our deposit pricing.

The deposit base remains well-diversified, with 53% of quarterly average client deposits coming from the Commercial, Small Business Banking, and Wealth and Trust businesses. No- and low-cost deposit accounts(6) represented 57% of average total client deposits with a weighted average cost of 28bps for the quarter. The loan-to-deposit ratio(7) was 71% at March 31, 2026, providing capacity to fund ongoing loan growth.

Net Interest Income

Three Months Ending

(Dollars in millions)

March 31, 2026

December 31, 2025

March 31, 2025

Net interest income before purchase accretion

$

183.5

$

186.0

$

173.1

Purchase accounting accretion

1.6

1.4

2.1

Net interest income

$

185.1

$

187.4

$

175.2

Net interest margin before purchase accretion

3.80

%

3.80

%

3.83

%

Purchase accounting accretion

0.03

0.03

0.05

Net interest margin

3.83

%

3.83

%

3.88

%

Net interest income decreased $2.2 million, or 1% (not annualized), compared to 4Q 2025, primarily driven by lower loan yields and higher interest expense on debt, partially offset by lower deposit costs and higher average loan balances.

Net interest income increased $9.9 million, or 6%, compared to 1Q 2025, primarily driven by higher cash balances from growth in deposits, lower deposit costs, and higher average loan balances. The increase was partially offset by lower loan yields.

Total loan yields were 6.27%, a decrease of 13bps when compared to 4Q 2025 and a decrease of 40bps when compared to 1Q 2025. The quarter-over-quarter and year-over-year decreases were primarily driven by the impact of interest rate cuts.

Total client deposit costs were 1.33% and interest-bearing deposit costs were 2.01%, decreases of 12bps and 16bps, respectively, compared to 4Q 2025. Total client deposit costs decreased 38bps and interest-bearing deposit costs decreased 42bps compared to 1Q 2025. The quarter-over-quarter and year-over-year decreases were driven by deposit repricing actions and a continued shift in the mix of deposits, with higher noninterest balances.

Net interest margin of 3.83% was flat compared to 4Q 2025 as lower deposit costs and loan growth were offset by lower loan yields and the higher debt expense noted above. Net interest margin decreased 5bps from 1Q 2025 primarily due to the impact of the three interest rate cuts that occurred in 2025.

Asset Quality

(Dollars in millions)

March 31, 2026

December 31, 2025

March 31, 2025

Problem assets(8)

$

503.9

$

535.9

$

683.7

Delinquencies (n)

100.7

168.4

147.7

Nonperforming assets (n)

87.8

72.1

116.9

Net (recoveries) charge-offs on loans and leases

(3.5

)

15.2

24.6

Total net credit costs (q)

0.2

12.0

17.6

Problem assets to total Tier 1 capital plus ACL on loans and leases

20.71

%

21.98

%

27.83

%

Classified assets to total Tier 1 capital plus ACL on loans and leases

17.19

17.59

20.80

Ratio of nonperforming assets to total assets (n)

0.40

0.34

0.57

Delinquencies (n) to gross loans (i)

0.76

1.27

1.13

Ratio of quarterly net (recoveries) charge-offs to average gross loans

(0.11

)

0.46

0.76

Ratio of allowance for credit losses to total loans and leases (p)

1.36

1.36

1.43

Ratio of allowance for credit losses to nonaccruing loans (n)

240

250

168

See “Notes”

Problem assets continued to trend downward, with a decrease of $32.0 million compared to December 31, 2025, largely driven by payoffs. Delinquencies decreased $67.7 million, or 51bps of gross loans, compared to December 31, 2025, driven by a significant reduction in commercial mortgage delinquencies. Problem assets decreased 26% and delinquencies decreased 32% compared to March 31, 2025.

Nonperforming assets (NPAs) increased $15.7 million, or 6bps of total assets compared to December 31, 2025. The increase in NPAs was primarily driven by a C&I loan of $11.2 million and a multifamily loan of $6.6 million, both of which are well-secured. NPAs are down 25% compared to March 31, 2025.

During the quarter, the Company transferred $12.7 million to other real estate owned related to a nonperforming land development loan.

As previously disclosed in our 2025 Form 10-K, we received payment for loans charged-off in the first quarter of 2025 to a fund invested in office properties, resulting in a recovery of $15.7 million and the payoff of a $2.5 million nonperforming loan. Net recoveries for the quarter were $3.5 million. Excluding the impacts of the recovery, net charge-offs on loans and leases were $12.2 million, a decrease of $2.9 million, or 8bps (annualized) of average gross loans, and total net credit costs increased by $3.9 million when compared to 4Q 2025. The increase in net credit costs was driven by timing-related loan workout costs and higher unfunded commitment reserves as a result of significant new originations.

The ACL on loans and leases was $180.0 million as of March 31, 2026, an increase of $0.4 million when compared to December 31, 2025, and the ACL coverage ratio was flat at 1.36%.

Core Fee Revenue(9)

Core fee revenue (noninterest income) of $90.1 million was flat compared to 4Q 2025. Wealth and Trust fees increased 9%, driven by double-digit growth in WSFS Institutional Services®, coupled with growth in Private Wealth Management and BMT of DE. This increase was offset by a $1.4 million decline in Cash Connect®, due to lower volume and rates (which was more than offset in noninterest expense), as well as lower income from equity investments and Capital Markets.

Core fee revenue increased $9.2 million, or 11%, compared to 1Q 2025. The increase was driven by broad-based double-digit growth across several businesses, including WSFS Institutional Services®, BMT of DE, Capital Markets, and WSFS Home Lending. These increases were partially offset by a $2.7 million decrease in Cash Connect®, primarily due to the impact of interest rate cuts and lower ATM volumes.

For 1Q 2026, our core fee revenue ratio(9) was 32.7% compared to 32.4% in 4Q 2025 and 31.5% in 1Q 2025. Fee revenue diversification is a differentiator with further growth opportunities expected.

Core Noninterest Expense(10)

Core noninterest expense of $159.9 million decreased $1.0 million, or 1% (not annualized), compared to 4Q 2025. The decrease is primarily due to a $2.1 million decline in salaries and benefits driven by the impact of higher performance-based incentives accrued in 4Q 2025, a $1.3 million decline in professional fees and a $1.1 million decline in Cash Connect® external funding costs due to lower rates and volume. These decreases were partially offset by increases from timing-related loan workout costs and higher unfunded commitment reserves as a result of significant new originations.

Core noninterest expense increased $8.4 million, or 6%, compared to 1Q 2025. The increase was primarily driven by a $9.2 million increase in salaries and benefits, driven by the impact of lower incentive payments made in the first quarter of 2025, higher salaries due to annual merit-based increases, and higher medical costs. In addition, loan workout and other credit costs, including unfunded commitment reserves, increased $1.9 million. These increases were partially offset by a $3.3 million decrease in Cash Connect® external funding costs due to lower ATM volume and rates.

Our core efficiency ratio(10) was 58.0% in 1Q 2026, compared to 57.9% in 4Q 2025 and 59.0% in 1Q 2025, reflecting our focus on expense discipline while continuing to invest in the franchise.

Income Taxes

We recorded a $27.6 million income tax provision in 1Q 2026, compared to $24.5 million in 4Q 2025 and $21.1 million in 1Q 2025. These increases were primarily due to higher income before taxes.

The effective tax rate was 24.1% in 1Q 2026 compared to 25.2% in 4Q 2025 and 24.3% in 1Q 2025. The decrease in effective tax rate compared to 4Q 2025 is primarily due to increased federal income tax credits and lower nondeductible expenses.

Capital Management

As part of our annual capital planning process, the Board of Directors approved an 18% increase in the quarterly cash dividend to $0.20 per share of common stock and an incremental share repurchase authorization of 15% of outstanding shares as of March 31, 2026. The dividend will be paid on May 22, 2026 to stockholders of record as of May 8, 2026. As a result of the incremental authorization, WSFS has 10,123,977 shares, or approximately 19% of outstanding shares as of March 31, 2026, available for repurchase.

Capital ratios remain strong and are all substantially in excess of the “well-capitalized” regulatory benchmarks at March 31, 2026, with a Common Equity Tier 1 capital ratio and Tier 1 capital ratio of 13.91%, Tier 1 leverage ratio of 10.51%, and Total Risk-based capital ratio of 15.66%.

During 1Q 2026, WSFS repurchased 1,319,626 shares of common stock for an aggregate of $85.0 million and paid quarterly cash dividends of $9.0 million. Total capital returns to stockholders through share repurchases and quarterly dividends was $94.0 million.

WSFS’ total stockholders’ equity decreased $14.1 million, or less than 1%, during 1Q 2026. The decrease was primarily due to capital returns to stockholders and an increase in accumulated other comprehensive loss of $8.5 million, driven by market-value decreases on available-for-sale investment securities. These decreases were partially offset by quarterly earnings of $86.8 million.

WSFS’ tangible common equity(11) decreased $10.5 million, or 1% (not annualized), compared to December 31, 2025, primarily due to the reasons described above. WSFS’ common equity to assets ratio decreased 53bps to 12.32% during the quarter. Our tangible common equity to tangible assets ratio(11) decreased 37bps to 8.32% during the quarter.

At March 31, 2026, book value per share was $52.24, an increase of $0.97, or 2% (not annualized), from December 31, 2025, and tangible book value per share(11) was $33.71, an increase of $0.60, or 2% (not annualized), from December 31, 2025. Book value per share increased $5.93, or 13%, and tangible book value per share increased $4.46, or 15%, compared to 1Q 2025.

Selected Business Segments (included in previous results):

Wealth and Trust

The Wealth and Trust segment provides a broad array of planning and advisory services, investment management, trust services, credit and deposit products to individual, corporate, and institutional Clients.

Selected quarterly performance results and metrics are as follows:

(Dollars in millions, except where otherwise noted)

March 31, 2026

December 31, 2025

March 31, 2025

Net interest income

$

27.5

$

27.2

$

20.3

Provision for credit losses

1.2

1.0

0.8

Fee revenue(12)

50.0

46.2

39.9

Noninterest expense(12)

31.8

32.1

30.0

Pre-tax income

44.5

40.2

29.4

Performance Metrics

WSFS Institutional Services® and BMT of DE fee revenue

$

34.2

$

31.3

$

24.3

Private Wealth Management fee revenue

15.9

15.5

15.1

AUM/AUA (in billions)(13)

97.6

97.4

89.6

Wealth and Trust pre-tax income was $44.5 million, which increased $4.3 million, or 11% (not annualized), compared to 4Q 2025, driven by an increase in fee revenue of $3.9 million, or 8%.

The increase in fee revenue was due to higher assignment, custody, and paying agent fees across WSFS Institutional Services® as well as higher AUM-based fees in Private Wealth Management. Net interest income increased $0.3 million or 1% (not annualized), due to higher noninterest deposit balances in Trust.

Wealth and Trust pre-tax income increased $15.1 million, or 52%, compared to 1Q 2025, driven by increases in fee revenue of $10.2 million, or 25%, and net interest income of $7.2 million, or 36%. These increases were partially offset by an increase in noninterest expense of $1.9 million, or 6%.

The increase in fee revenue was driven by growth in WSFS Institutional Services® and BMT of DE, while the increase in net interest income was due to higher noninterest deposit balances in Trust. The increase in noninterest expense was primarily due to lower incentive payments made in the first quarter of 2025.

AUM/AUA increased by $0.2 billion to $97.6 billion at the end of 1Q 2026, as client inflows outpaced market depreciation and client spend.

Cash Connect®

Cash Connect® is a premier provider of ATM vault cash, smart safe and cash logistics services in the United States, servicing non-bank ATMs and smart safes nationwide and supporting ATMs for WSFS Bank Clients.

Selected quarterly financial results and metrics are as follows:

(Dollars in millions)

March 31, 2026

December 31, 2025

March 31, 2025

Net revenue(14)

$

19.6

$

20.7

$

21.5

Noninterest expense(15)

16.7

18.1

19.9

Pre-tax income

3.0

2.6

1.6

Performance Metrics

Average cash managed

$

1,251

$

1,292

$

1,407

Number of serviced non-bank ATMs and smart safes

35,338

35,958

38,214

Net profit margin

15.4

%

12.7

%

7.4

%

ROA

2.38

%

2.11

%

1.21

%

Cash Connect® net profit margin of 15.4% increased 267bps compared to 4Q 2025, and increased 799bps compared to 1Q 2025.

Pre-tax income of $3.0 million in 1Q 2026 increased $0.4 million, or 14% (not annualized), compared to 4Q 2025. Net revenue decreased $1.1 million and noninterest expense decreased $1.4 million compared to 4Q 2025, both driven by lower volume and lower interest rates.

Compared to 1Q 2025, pre-tax income increased $1.5 million, driven by the impact of lower interest rates (lower revenues were more than offset by lower expenses), pricing initiatives (increased revenues), and expense optimization, which more than offset overall ATM volume declines.

Cash Connect® continues to shift its business mix from traditional non-bank ATMs to higher margin products, such as smart safes, which have grown 14% year over year.

First Quarter 2026 Earnings Release Conference Call

Management will conduct a conference call to review 1Q 2026 results at 1:00 p.m. Eastern Time (ET) on Friday, April 24, 2026. Interested parties may access the conference call live on our Investor Relations website (https://investors.wsfsbank.com). For those who cannot access the live conference call, a replay will be accessible shortly after the event concludes through our Investor Relations website.

About WSFS Financial Corporation

WSFS Financial Corporation is a multibillion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally headquartered bank and wealth management franchise in the Greater Philadelphia and Delaware region. As of March 31, 2026, WSFS Financial Corporation had $22.1 billion in assets on its balance sheet and $97.6 billion in assets under management and administration. WSFS operates from 114 offices, 87 of which are banking offices, located in Pennsylvania (58), Delaware (38), New Jersey (14), Florida (2), Nevada (1) and Virginia (1) and provides comprehensive financial services including commercial banking, consumer banking, treasury management, and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Bryn Mawr Trust Advisors, LLC, Bryn Mawr Trust®, The Bryn Mawr Trust Company of Delaware, Cash Connect®, NewLane Finance®, WSFS Wealth® Management, LLC, WSFS Institutional Services®, and WSFS Mortgage®. Serving the Greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit www.wsfsbank.com.

Forward-Looking Statements

This press release contains estimates, predictions, opinions, projections and other "forward-looking statements" as that phrase is defined in the Private Securities Litigation Reform Act of 1995. Such statements include, without limitation, references to the Company's predictions or expectations of future business or financial performance as well as its goals and objectives for future operations, financial and business trends, business prospects, and management's outlook or expectations for earnings, revenues, expenses, capital levels, liquidity levels, asset quality or other future financial or business performance, strategies or expectations. The words “believe,” “expect,” “anticipate,” “plan,” “estimate,” “target,” “project” and similar expressions, among others, generally identify forward-looking statements. Such forward-looking statements are based on various assumptions (some of which may be beyond the Company's control) and are subject to risks and uncertainties (which change over time) and other factors which could cause actual results to differ materially from those currently anticipated. Such risks and uncertainties include, but are not limited to, difficult market conditions and unfavorable economic trends in the United States generally and in financial markets, particularly in the markets in which the Company operates and in which its loans are concentrated, including difficult and unfavorable conditions and trends related to housing markets, costs of living, unemployment levels, interest rates, supply chain issues, inflation, and economic growth; possible additional loan losses and impairment of the collectability of loans; the Company's level of nonperforming assets and the costs associated with resolving problem loans including litigation and other costs and complying with government-imposed foreclosure moratoriums; the credit risk associated with the substantial amount of commercial real estate, commercial and industrial, and construction and land development loans in the Company's loan portfolio; changes in market interest rates, which may increase funding costs and reduce earning asset yields and thus reduce margin; the impact of changes in interest rates and the credit quality and strength of underlying collateral and the effect of such changes on the market value of the Company's investment securities portfolio, which could impact market confidence in the Company's operations; the extensive federal and state regulation, supervision and examination governing almost every aspect of the Company's operations, and potential expenses associated with complying with such regulations; the Company's ability to comply with applicable capital and liquidity requirements, including its ability to generate liquidity internally or raise capital on favorable terms; the impacts related to or resulting from bank failures and other economic industry volatility, including potential increased regulatory requirements and costs and potential impacts to macroeconomic conditions; changes in trade, monetary and fiscal policies and stimulus programs, laws and regulations and other activities of governments, agencies, and similar organizations, and the uncertainty of the short- and long-term impacts of such changes; any impairments of the Company's goodwill or other intangible assets; the success of the Company's growth plans across our WSFS Bank, Cash Connect® and/or Wealth and Trust segments; the Company's ability to successfully integrate and fully realize the cost savings and other benefits of its acquisitions, manage risks related to business disruption following those acquisitions, and post-acquisition Client acceptance of the Company's products and services and related Client disintermediation; negative perceptions or publicity with respect to the Company generally and, in particular, the Company's Wealth and Trust business; failure of the financial and/or operational controls of the Company's Cash Connect® and/or Wealth and Trust segments; adverse judgments or other resolution of pending and future legal proceedings, and costs incurred in defending such proceedings; the Company's reliance on third parties for certain important functions, including the operation of its core systems, and any failures by such third parties; system failures or cybersecurity incidents or other breaches of the Company's network security, particularly given remote working arrangements; any actual or perceived failure or deficiency in the use of artificial intelligence by the Company or third-party vendors or service providers; the Company's ability to recruit and retain key Associates; the effects of weather, including climate change, and natural disasters such as floods, droughts, wind, tornadoes, wildfires and hurricanes as well as effects from geopolitical instability, armed conflicts, public health crises and man-made disasters including terrorist attacks; the effects of regional or national civil unrest (including any resulting branch or ATM closures or damage); possible changes in the speed of loan prepayments by the Company's Clients and loan origination or sales volumes; possible changes in market valuations and/or the speed of prepayments of mortgage-backed securities (MBS) due to changes in the interest rate environment, and the related acceleration of premium amortization on prepayments in the event that prepayments accelerate; regulatory limits on the Company's ability to receive dividends from its subsidiaries, and pay dividends to its stockholders; any reputation, credit, interest rate, market, operational, litigation, legal, liquidity, regulatory and compliance risk resulting from developments related to any of the risks discussed above; any compounding effects or unexpected interactions of the risks discussed above; and other risks and uncertainties, including those discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025 under the heading “Risk Factors” and in other documents filed by the Company with the Securities and Exchange Commission from time to time.

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. The Company disclaims any duty to revise or update any forward-looking statement, whether written or oral, that may be made from time to time by or on behalf of the Company for any reason, except as specifically required by law. As used in this press release, the terms "WSFS," "the Company," "registrant," "we," "us," and "our" mean WSFS Financial Corporation and its subsidiaries, on a consolidated basis, unless the context indicates otherwise.

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS

SUMMARY STATEMENTS OF INCOME (Unaudited)

  Three months ended

(Dollars in thousands, except per share data)

March 31, 2026

December 31, 2025

March 31, 2025

Interest income:

Interest and fees on loans

$

205,243

$

212,247

$

216,752

Interest on mortgage-backed securities

25,242

24,526

24,745

Interest and dividends on investment securities

2,171

2,170

2,186

Other interest income

16,553

18,256

7,195

249,209

257,199

250,878

Interest expense:

Interest on deposits

59,497

65,847

71,104

Interest on Federal Home Loan Bank advances

439

980

938

Interest on senior and subordinated debt

2,766

1,520

2,074

Interest on trust preferred borrowings

1,355

1,483

1,523

Interest on other borrowings

16

16

23

64,073

69,846

75,662

Net interest income

185,136

187,353

175,216

(Recovery of) provision for credit losses

(1,998

)

12,669

17,350

Net interest income after (recovery of) provision for credit losses

187,134

174,684

157,866

Noninterest income:

Credit/debit card and ATM income

15,066

16,804

18,743

Investment management and fiduciary revenue

49,127

45,127

39,281

Deposit service charges

6,877

6,972

6,753

Mortgage banking activities, net

2,361

2,127

1,800

Loan and lease fee income

2,002

2,084

1,465

Unrealized loss on equity investment, net

—

(4,057

)

—

Other income

14,682

15,464

12,855

90,115

84,521

80,897

Noninterest expense:

Salaries, benefits and other compensation

91,887

93,548

82,477

Occupancy expense

10,139

8,340

9,893

Equipment expense

13,272

13,501

12,728

Data processing and operations expense

5,011

5,195

4,695

Professional fees

4,118

5,420

4,698

Marketing expense

2,135

2,639

1,695

FDIC expenses

2,634

2,544

2,578

Loss on debt extinguishment

—

1,151

—

Loan workout and other credit costs

2,174

(696

)

240

Corporate development expense

57

55

59

Restructuring expense

2,796

(126

)

260

Other operating expenses

28,542

30,402

32,472

162,765

161,973

151,795

Income before taxes

114,484

97,232

86,968

Income tax provision

27,639

24,538

21,101

Net income

86,845

72,694

65,867

Less: Net income (loss) attributable to noncontrolling interest

18

16

(29

)

Net income attributable to WSFS

$

86,827

$

72,678

$

65,896

Diluted earnings per share of common stock:

$

1.64

$

1.34

$

1.12

Weighted average shares of common stock outstanding for fully diluted EPS

53,031,912

54,369,944

58,713,452

See “Notes”

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS

SUMMARY STATEMENTS OF INCOME (Unaudited) - continued

  Three months ended

March 31, 2026

December 31, 2025

March 31, 2025

Performance Ratios:

Return on average assets (a)

1.61

%

1.33

%

1.29

%

Return on average equity (a)

12.71

10.51

10.13

Return on average tangible common equity (a)(o)

20.18

16.91

16.91

Net interest margin (a)(b)

3.83

3.83

3.88

Efficiency ratio (c)

59.0

59.5

59.2

Noninterest income as a percentage of total net revenue (b)

32.7

31.0

31.5

See “Notes”

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS (Continued)

SUMMARY STATEMENTS OF FINANCIAL CONDITION (Unaudited)

  (Dollars in thousands)

March 31, 2026

December 31, 2025

March 31, 2025

Assets:

Cash and due from banks

$

2,067,824

$

1,326,339

$

693,830

Cash in non-owned ATMs

397,877

363,926

322,520

Investment securities, available-for-sale

3,581,894

3,542,246

3,548,077

Investment securities, held-to-maturity

958,219

968,331

1,006,410

Other investments

43,291

32,524

39,552

Net loans and leases (e)(f)(l)

13,153,815

13,143,600

12,975,323

Goodwill and intangibles

966,388

969,903

983,882

Other assets

937,607

967,207

979,356

Total assets

$

22,106,915

$

21,314,076

$

20,548,950

Liabilities and Stockholders’ Equity:

Noninterest-bearing deposits

$

6,371,522

$

5,576,598

$

4,947,049

Interest-bearing deposits

12,096,966

12,065,890

11,932,012

Total client deposits

18,468,488

17,642,488

16,879,061

Federal Home Loan Bank advances

—

—

51,040

Other borrowings

310,355

302,682

267,052

Other liabilities

614,031

640,831

690,588

Total liabilities

19,392,874

18,586,001

17,887,741

Stockholders’ equity of WSFS

2,724,493

2,738,545

2,671,614

Noncontrolling interest

(10,452

)

(10,470

)

(10,405

)

Total stockholders' equity

2,714,041

2,728,075

2,661,209

Total liabilities and stockholders' equity

$

22,106,915

$

21,314,076

$

20,548,950

Capital Ratios:

Equity to asset ratio

12.32

%

12.85

%

13.00

%

Tangible common equity to tangible asset ratio (o)

8.32

8.69

8.63

Common equity Tier 1 capital (required: 4.5%; well capitalized: 6.5%) (g)

13.91

13.92

14.10

Tier 1 leverage (required: 4.00%; well-capitalized: 5.00%) (g)

10.51

10.59

11.17

Tier 1 risk-based capital (required: 6.00%; well-capitalized: 8.00%) (g)

13.91

13.92

14.10

Total risk-based capital (required: 8.00%; well-capitalized: 10.00%) (g)

15.66

15.67

15.89

Asset Quality Indicators:

Nonperforming assets:

Nonaccruing loans (s)(n)

$

75,112

$

71,898

$

111,675

Assets acquired through foreclosure

12,717

200

5,204

Total nonperforming assets

$

87,829

$

72,098

$

116,879

Past due loans (h)(n)

$

12,029

$

22,416

$

11,866

Troubled loans (t)(n)

110,586

144,267

184,122

Allowance for credit losses

182,876

182,500

188,088

Ratio of nonperforming assets to total assets (n)

0.40

%

0.34

%

0.57

%

Ratio of allowance for credit losses to total loans and leases (p)

1.36

1.36

1.43

Ratio of allowance for credit losses to nonaccruing loans (n)

240

250

168

Ratio of quarterly net (recoveries) charge-offs to average gross loans (a)(e)(i)

(0.11

)

0.46

0.76

Ratio of year-to-date net (recoveries) charge-offs to average gross loans (a)(e)(i)

(0.11

)

0.45

0.76

See “Notes”

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS (Continued)

AVERAGE BALANCE SHEET (Unaudited)

  (Dollars in thousands)

Three months ended

March 31, 2026

December 31, 2025

March 31, 2025

Average

Balance

Interest &

Dividends

Yield/

Rate

(a)(b)

Average

Balance

Interest &

Dividends

Yield/

Rate

(a)(b)

Average

Balance

Interest &

Dividends

Yield/

Rate

(a)(b)

Assets:

Interest-earning assets:

Loans: (e) (j)

Commercial loans

$

4,701,069

$

70,169

6.07

%

$

4,623,319

$

72,389

6.23

%

$

4,598,599

$

73,154

6.45

%

Commercial real estate loans (r)

4,968,948

76,339

6.23

4,916,393

79,765

6.44

4,881,873

79,095

6.57

Commercial leases

588,782

12,850

8.73

604,445

13,216

8.75

636,912

13,958

8.77

Residential mortgage

1,089,151

14,638

5.38

1,059,006

14,056

5.31

965,624

12,802

5.30

Consumer loans

1,871,601

29,847

6.47

1,896,878

31,498

6.59

2,061,803

36,649

7.21

Loans held for sale

66,760

1,400

8.50

69,230

1,323

7.58

50,929

1,094

8.71

Total loans and leases

13,286,311

205,243

6.27

13,169,271

212,247

6.40

13,195,740

216,752

6.67

Mortgage-backed securities (d)

4,191,264

25,242

2.41

4,136,381

24,526

2.37

4,179,692

24,745

2.37

Investment securities (d)

368,318

2,171

2.72

367,731

2,170

2.66

363,678

2,186

2.74

Other interest-earning assets

1,793,908

16,553

3.74

1,795,895

18,256

4.03

640,424

7,195

4.56

Total interest-earning assets

$

19,639,801

$

249,209

5.16

%

$

19,469,278

$

257,199

5.25

%

$

18,379,534

$

250,878

5.55

%

Allowance for credit losses

(184,109

)

(184,484

)

(196,480

)

Cash and due from banks

175,052

166,442

188,138

Cash in non-owned ATMs

351,909

347,883

379,115

Bank owned life insurance

37,289

36,946

36,202

Other noninterest-earning assets

1,855,211

1,861,713

1,947,736

Total assets

$

21,875,153

$

21,697,778

$

20,734,245

Liabilities and stockholders’ equity:

Interest-bearing liabilities:

Interest-bearing deposits:

Interest-bearing demand

$

2,828,403

$

6,055

0.87

%

$

2,861,099

$

7,163

0.99

%

$

2,854,258

$

7,343

1.04

%

Savings

1,395,028

1,163

0.34

1,413,087

1,652

0.46

1,457,440

1,596

0.44

Money market

5,817,813

36,876

2.57

5,708,666

38,871

2.70

5,432,622

41,033

3.06

Time deposits

1,962,289

15,403

3.18

2,047,200

18,158

3.52

2,112,467

21,132

4.06

Total interest-bearing client deposits

12,003,533

59,497

2.01

12,030,052

65,844

2.17

11,856,787

71,104

2.43

Brokered deposits

—

—

—

315

3

3.78

—

—

—

Total interest-bearing deposits

12,003,533

59,497

2.01

12,030,367

65,847

2.17

11,856,787

71,104

2.43

Federal Home Loan Bank advances

44,444

439

4.01

86,957

980

4.47

83,818

938

4.54

Trust preferred borrowings

91,055

1,355

6.04

91,001

1,483

6.47

90,854

1,523

6.80

Senior and subordinated debt

196,919

2,766

5.62

159,787

1,520

3.81

206,984

2,074

4.01

Other borrowed funds

21,868

16

0.30

20,846

16

0.30

31,701

23

0.29

Total interest-bearing liabilities

$

12,357,819

$

64,073

2.10

%

$

12,388,958

$

69,846

2.24

%

$

12,270,144

$

75,662

2.50

%

Noninterest-bearing demand deposits

6,105,690

5,955,352

5,040,032

Other noninterest-bearing liabilities

652,541

621,484

797,098

Stockholders’ equity of WSFS

2,769,574

2,742,480

2,637,354

Noncontrolling interest

(10,471

)

(10,496

)

(10,383

)

Total liabilities and equity

$

21,875,153

$

21,697,778

$

20,734,245

Excess of interest-earning assets over interest-bearing liabilities

$

7,281,982

$

7,080,320

$

6,109,390

Net interest and dividend income

$

185,136

$

187,353

$

175,216

Interest rate spread

3.06

%

3.01

%

3.05

%

Net interest margin

3.83

%

3.83

%

3.88

%

See “Notes”

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS (Continued)

(Unaudited)

(Dollars in thousands, except per share data)

Three months ended

Stock Information:

March 31, 2026

December 31, 2025

March 31, 2025

Market price of common stock:

High

$71.32

$58.86

$59.43

Low

54.31

49.92

49.65

Close

65.46

55.24

51.87

Book value per share of common stock

52.24

51.27

46.31

Tangible common book value (TBV) per share of common stock (o)

33.71

33.11

29.25

Number of shares of common stock outstanding (000s)

52,149

53,410

57,693

Other Financial Data:

One-year repricing gap to total assets (k)

11.50%

8.37%

2.30%

Weighted average duration of the MBS portfolio

5.8 years

5.8 years

6.1 years

Unrealized losses on securities available for sale, net of taxes

$(385,270)

$(376,545)

$(467,752)

Number of Associates (FTEs) (m)

2,348

2,335

2,336

Number of offices (branches, LPO’s, operations centers, etc.)

114

113

115

Notes:

(a)

Annualized.

(b)

Computed on a fully tax-equivalent basis.

(c)

Noninterest expense divided by (tax-equivalent) net interest income and noninterest income.

(d)

Includes securities held-to-maturity (at amortized cost) and securities available-for-sale (at fair value).

(e)

Net of unearned income.

(f)

Net of allowance for credit losses.

(g)

Represents capital ratios of Wilmington Financial Corporation and subsidiaries. Capital Ratios for the current quarter are to be considered preliminary until the Call Reports are filed.

(h)

Accruing loans which are contractually past due 90 days or more as to principal or interest. Balance includes student loans, which are U.S. government guaranteed with little risk of credit loss.

(i)

Excludes loans held for sale and reverse mortgage loans.

(j)

Nonperforming loans are included in average balance computations.

(k)

The difference between projected amounts of interest-sensitive assets and interest-sensitive liabilities repricing within one year divided by total assets, based on a current interest rate scenario.

(l)

Includes loans held for sale and reverse mortgages.

(m)

Includes seasonal Associates, when applicable.

(n)

Includes loans held for sale.

(o)

The Company uses non-GAAP (United States Generally Accepted Accounting Principles) financial information in its analysis of the Company’s performance. The Company’s management believes that these non-GAAP financial measures provide a greater understanding of ongoing operations, enhance comparability of results of operations with prior periods and show the effects of significant gains and charges in the periods presented. The Company’s management believes that investors may use these non-GAAP financial measures to analyze the Company’s financial performance without the impact of unusual items or events that may obscure trends in the Company’s underlying performance. This non-GAAP data should be considered in addition to results prepared in accordance with GAAP, and is not a substitute for, or superior to, GAAP results. For a reconciliation of these and other non-GAAP financial measures to their most directly comparable GAAP measures, see "Non-GAAP Reconciliation" at the end of the press release.

(p)

Reflects allowance for credit losses on loans and leases over the amortized cost of the total portfolio.

(q)

Includes provision for credit losses, loan workout expenses, OREO expenses and other credit costs.

(r)

Includes commercial mortgage and commercial construction loans.

(s)

Includes nonaccruing troubled loans.

(t)

Represents loans modified in the form of principal forgiveness, interest rate reduction, an other-than-insignificant payment delay, or a term extension to borrowers experiencing financial difficulty.

WSFS FINANCIAL CORPORATION

FINANCIAL HIGHLIGHTS (Continued)

(Dollars in thousands, except per share data)

(Unaudited)

  Non-GAAP Reconciliation (o):

Three months ended

March 31, 2026

December 31, 2025

March 31, 2025

Net interest income (GAAP)

$

185,136

$

187,353

$

175,216

Core net interest income (non-GAAP)

185,136

187,353

175,216

Noninterest income (GAAP)

90,115

84,521

80,897

Plus: Unrealized loss on equity investments, net

—

(4,057

)

—

Plus: Visa derivative valuation adjustment

—

(1,500

)

—

Core fee revenue (non-GAAP)

$

90,115

$

90,078

$

80,897

Core net revenue (non-GAAP)

$

275,251

$

277,431

$

256,113

Core net revenue (non-GAAP)(tax-equivalent)

$

275,780

$

277,957

$

256,568

Noninterest expense (GAAP)

$

162,765

$

161,973

$

151,795

Less: Loss on debt extinguishment

—

1,151

—

Less: Corporate development expense

57

55

59

Less/(plus): Restructuring expense

2,796

(126

)

260

Core noninterest expense (non-GAAP)

$

159,912

$

160,893

$

151,476

Core efficiency ratio (non-GAAP)

58.0

%

57.9

%

59.0

%

Core fee revenue ratio (non-GAAP) (b)

32.7

%

32.4

%

31.5

%

End of period

March 31, 2026

December 31, 2025

March 31, 2025

Total assets (GAAP)

$

22,106,915

$

21,314,076

$

20,548,950

Less: Goodwill and other intangible assets

966,388

969,903

983,882

Total tangible assets (non-GAAP)

$

21,140,527

$

20,344,173

$

19,565,068

Total stockholders’ equity of WSFS (GAAP)

$

2,724,493

$

2,738,545

$

2,671,614

Less: Goodwill and other intangible assets

966,388

969,903

983,882

Total tangible common equity (non-GAAP)

$

1,758,105

$

1,768,642

$

1,687,732

Tangible common book value (TBV) per share:

Book value per share (GAAP)

$

52.24

$

51.27

$

46.31

Tangible common book value per share (non-GAAP)

33.71

33.11

29.25

Tangible common equity to tangible assets:

Equity to asset ratio (GAAP)

12.32

%

12.85

%

13.00

%

Tangible common equity to tangible assets ratio (non-GAAP)

8.32

8.69

8.63

Non-GAAP Reconciliation - continued (o):

Three months ended

March 31, 2026

December 31, 2025

March 31, 2025

GAAP net income attributable to WSFS

$

86,827

$

72,678

$

65,896

Plus/(less): Pre-tax adjustments: Unrealized loss on equity investments, net, Visa derivative valuation adjustment, loss on debt extinguishment, corporate development and restructuring expense

2,853

6,637

319

(Less)/plus: Tax impact of pre-tax adjustments

(639

)

(1,637

)

(78

)

Adjusted net income (non-GAAP) attributable to WSFS

$

89,041

$

77,678

$

66,137

GAAP return on average assets (ROA)

1.61

%

1.33

%

1.29

%

Plus/(less): Pre-tax adjustments: Unrealized loss on equity investments, net, Visa derivative valuation adjustment, loss on debt extinguishment, corporate development and restructuring expense

0.05

0.12

0.01

(Less)/plus: Tax impact of pre-tax adjustments

(0.01

)

(0.03

)

(0.01

)

Core ROA (non-GAAP)

1.65

%

1.42

%

1.29

%

Less: Impact of loan recovery (after-tax)

0.22

—

—

Core ROA excluding loan recovery (non-GAAP)

1.43

%

1.42

%

1.29

%

Earnings per share (diluted) (GAAP)

$

1.64

$

1.34

$

1.12

Plus/(less): Pre-tax adjustments: Unrealized loss on equity investments, net, Visa derivative valuation adjustment, loss on debt extinguishment, corporate development and restructuring expense

0.05

0.12

0.01

(Less)/plus: Tax impact of pre-tax adjustments

(0.01

)

(0.03

)

—

Core earnings per share (non-GAAP)

$

1.68

$

1.43

$

1.13

Less: Impact of loan recovery (after-tax)

0.23

—

—

Core EPS excluding loan recovery (non-GAAP)

$

1.45

$

1.43

$

1.13

Calculation of return on average tangible common equity:

GAAP net income attributable to WSFS

$

86,827

$

72,678

$

65,896

Plus: Tax effected amortization of intangible assets

2,778

2,782

2,945

Net tangible income (non-GAAP)

$

89,605

$

75,460

$

68,841

Average stockholders’ equity of WSFS

$

2,769,574

$

2,742,480

$

2,637,354

Less: Average goodwill and intangible assets

968,555

972,332

986,738

Net average tangible common equity

$

1,801,019

$

1,770,148

$

1,650,616

Return on average tangible common equity (non-GAAP)

20.18

%

16.91

%

16.91

%

Calculation of PPNR:

Net income (GAAP)

$

86,845

$

72,694

$

65,867

Plus: Income tax provision

27,639

24,538

21,101

(Less)/plus: (Recovery of) provision for credit losses

(1,998

)

12,669

17,350

PPNR (non-GAAP)

$

112,486

$

109,901

$

104,318

WSFS Financial (WSFS - Free Report) reported $275.25 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 7.5%. EPS of $1.45 for the same period compares to $1.13 a year ago.

The reported revenue represents a surprise of +1.45% over the Zacks Consensus Estimate of $271.32 million. With the consensus EPS estimate being $1.48, the EPS surprise was -2.03%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how WSFS performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

Efficiency Ratio: 59% versus 59.2% estimated by two analysts on average.Net Interest Margin: 3.8% versus the two-analyst average estimate of 3.8%.Common equity Tier 1 capital: 13.9% versus 14% estimated by two analysts on average.Net Interest Income: $185.14 million versus $183.14 million estimated by two analysts on average.Total Non-Interest Income: $90.12 million versus $88.18 million estimated by two analysts on average.Mortgage banking activities, net: $2.36 million versus $1.58 million estimated by two analysts on average.View all Key Company Metrics for WSFS here>>>

Shares of WSFS have returned +7% over the past month versus the Zacks S&P 500 composite's +9.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

92% report meeting or exceeding their expectations despite inflation and tariff concerns

WILMINGTON, Del.--(BUSINESS WIRE)--Small business owners and senior decision-makers in the Mid-Atlantic region are reporting strong resilience. Despite persistent inflation and tariff-related uncertainty, 92% say their businesses are currently meeting or exceeding their performance expectations. According to a new survey from WSFS Bank, the primary subsidiary of WSFS Financial Corporation (Nasdaq: WSFS), optimism is equally strong looking ahead, with 66% of respondents agreeing their businesses will grow over the next 12 months.

“Small business owners have proven to be skilled navigators of uncertainty, turning economic challenges into opportunities for refinement,” said Candice Caruso, Senior Vice President, Chief Business Banking Officer, WSFS Bank.

Share The survey, which polled 505 small business decision-makers, found larger organizations with 100 to 499 employees and newer organizations founded within the last five years to be the most confident, with 77% in each group expressing optimism for their next year of operations. More than half of all owners and decision-makers (52%) also expect revenue to increase over the coming year. These findings suggest that despite a volatile economic backdrop, small business owners are finding effective ways to sustain and build momentum.

“Small business owners have proven to be skilled navigators of uncertainty, turning economic challenges into opportunities for refinement,” said Candice Caruso, Senior Vice President, Chief Business Banking Officer, WSFS Bank. “At WSFS, we aim to meet businesses where they are. Whether they need assistance managing cash flow or seeking guidance to manage risk, we’re proud to provide the lending options and advisory support to help owners grow their businesses in any economic climate.”

Challenges Facing Small Businesses
Despite the overall positive outlook, economic uncertainty and inflation continue to weigh heavily on the small business community. Among leaders surveyed who reported negative impacts, 52% cited inflation as the primary driver of decreased performance, followed by the cost-of-living crisis (43%), tariff-related uncertainty (40%), and recession concerns (33%).

However, business owners are taking proactive steps to protect their cash flow. More than half (51%) have reduced non-essential spending, while 31% have shifted to lower-cost suppliers and 27% have renegotiated contracts with existing vendors. These strategic shifts and creative solutions for marketing and content creation reflect a broader pattern of pragmatic adaptability in the face of external pressures.

Banking Expectations and Partnership Satisfaction
The survey also explored what small business owners expect from their banking relationships. Overall satisfaction between small businesses and their banking partners remains high at 84%, though the data suggests that smaller, newer, and lower-revenue businesses may benefit from deeper banking relationships that provide additional expertise and resources to help them succeed.

"Our Associates are focused on helping business owners connect the dots from managing day-to-day financial needs to planning for long-term growth," Caruso said. "As a trusted advisor, we provide guidance that’s practical, personalized, and grounded in what each business is trying to achieve."

The Role of Artificial Intelligence (AI)
Technology plays an increasingly central role in how small businesses operate. Four in five (81%) respondents report using AI tools for at least one business function, with data analysis and information gathering (43%) and marketing and content creation (42%) emerging as the top use cases. Technology adoption is widespread for larger businesses with annual revenues above $250K integrating these tools at more advanced rates than their smaller counterparts, suggesting that resources and scale continue to shape how businesses embrace AI.

Survey Methodology
The survey was conducted by market research and insights agency Opinium. The sample includes a survey of 505 small business owners/decision-makers in the Mid-Atlantic region, with annual revenues of up to $5 million and a minimum of two employees. All respondents were over the age of 18. The online survey was conducted from March 18 – March 28th, 2026. It has a margin of error of +/- 4 percent.

Learn more about the survey at wsfsbank.com/smallbusinesssurvey.

About Opinium, Inc.
Opinium is an award-winning strategic market research and insights agency built on the belief that in a world of uncertainty and complexity, success depends on the ability to stay on pulse of what people think, feel and do. Creative and inquisitive, Opinium is passionate about empowering clients to make the decisions that matter. The company works with organizations to define and overcome strategic challenges – helping them to get to grips with the world in which their brands operate. Opinium uses the right approach and methodology to deliver robust insights, strategic counsel and targeted recommendations that generate change and positive outcomes.

About WSFS Financial Corporation
WSFS Financial Corporation is a multibillion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally headquartered bank and wealth management franchise in the Greater Philadelphia and Delaware region. As of March 31, 2026, WSFS Financial Corporation had $22.1 billion in assets on its balance sheet and $97.6 billion in assets under management and administration. WSFS operates from 114 offices, 87 of which are banking offices, located in Pennsylvania (58), Delaware (38), New Jersey (14), Florida (2), Nevada (1) and Virginia (1) and provides comprehensive financial services including commercial banking, consumer banking, treasury management, and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Bryn Mawr Trust Advisors, LLC, Bryn Mawr Trust®, The Bryn Mawr Trust Company of Delaware, Cash Connect®, NewLane Finance®, WSFS Wealth® Management, LLC, WSFS Institutional Services®, and WSFS Mortgage®. Serving the Greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit www.wsfsbank.com.

WILMINGTON, Del.--(BUSINESS WIRE)--WSFS Financial Corporation (Nasdaq: WSFS), the parent company of WSFS Bank, rang the Nasdaq Closing Bell on Tuesday, June 2, 2026, marking its 40th year listed as a publicly traded company on the exchange. The milestone, along with WSFS’ nearly 200-year history, highlights the growth, innovation, and service of the company.

“Reaching this milestone reflects both our financial strength and the deep relationships we’ve built with our Clients, Communities, and fellow Associates,” said WSFS Chairman, President, and Chief Executive Officer, Rodger Levenson.

To celebrate the occasion, Levenson rang the bell alongside a group of WSFS Associates, including those who have been with the organization for 40 years or more.

“A company is only as strong as the people who build it,” said Levenson. “Our Associates have helped us build the strong culture we rely on today and their dedication is the blueprint for our continued success.”

WSFS is the oldest and largest locally headquartered bank in the Greater Philadelphia and Delaware region.

Watch the ceremony at https://www.nasdaq.com/events/wsfs-financial-corporation-rings-closing-bell.

About WSFS Financial Corporation

WSFS Financial Corporation is a multibillion-dollar financial services company. Its primary subsidiary, WSFS Bank, is the oldest and largest locally headquartered bank and wealth management franchise in the Greater Philadelphia and Delaware region. As of March 31, 2026, WSFS Financial Corporation had $22.1 billion in assets on its balance sheet and $97.6 billion in assets under management and administration. WSFS operates from 114 offices, 87 of which are banking offices, located in Pennsylvania (58), Delaware (38), New Jersey (14), Florida (2), Nevada (1) and Virginia (1) and provides comprehensive financial services including commercial banking, consumer banking, treasury management, and trust and wealth management. Other subsidiaries or divisions include Arrow Land Transfer, Bryn Mawr Trust Advisors, LLC, Bryn Mawr Trust®, The Bryn Mawr Trust Company of Delaware, Cash Connect®, NewLane Finance®, WSFS Wealth® Management, LLC, WSFS Institutional Services®, and WSFS Mortgage®. Serving the Greater Delaware Valley since 1832, WSFS Bank is one of the ten oldest banks in the United States continuously operating under the same name. For more information, please visit www.wsfsbank.com.

Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.50, moving -6.17% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.41%. At the same time, the Dow lost 0.36%, and the tech-heavy Nasdaq lost 0.89%.

Shares of the biotechnology company have appreciated by 17.67% over the course of the past month, outperforming the Medical sector's gain of 0.47%, and the S&P 500's gain of 9.71%.

Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. It is anticipated that the company will report an EPS of -$0.27, marking a 46% rise compared to the same quarter of the previous year. Simultaneously, our latest consensus estimate expects the revenue to be $20.73 million, showing a 40.65% escalation compared to the year-ago quarter.

RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $90.52 million. These results would represent year-over-year changes of +35.42% and +21.21%, respectively.

Investors should also pay attention to any latest changes in analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Recursion Pharmaceuticals holds a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 143, positioning it in the bottom 42% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow RXRX in the coming trading sessions, be sure to utilize Zacks.com.

Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST Company to host public Earnings Call on May 6 at 8:00 am ET / 6:00 am MT / 1:00 pm BST

In the latest close session, Recursion Pharmaceuticals (RXRX - Free Report) was down 1.45% at $3.41. This move lagged the S&P 500's daily gain of 0.29%. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.89%.

The stock of biotechnology company has risen by 11.25% in the past month, leading the Medical sector's gain of 0.32% and the S&P 500's gain of 10.54%.

Investors will be eagerly watching for the performance of Recursion Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on May 6, 2026. The company is predicted to post an EPS of -$0.27, indicating a 46% growth compared to the equivalent quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $20.73 million, up 40.65% from the year-ago period.

RXRX's full-year Zacks Consensus Estimates are calling for earnings of -$0.93 per share and revenue of $90.52 million. These results would represent year-over-year changes of +35.42% and +21.21%, respectively.

Investors might also notice recent changes to analyst estimates for Recursion Pharmaceuticals. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.

The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Recursion Pharmaceuticals presently features a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 41% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Recursion Pharmaceuticals (RXRX - Free Report) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +25.42%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.28 per share when it actually produced a loss of $0.21, delivering a surprise of +25%.

Over the last four quarters, the company has surpassed consensus EPS estimates three times.

Recursion Pharmaceuticals, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $6.47 million for the quarter ended March 2026, missing the Zacks Consensus Estimate by 60.08%. This compares to year-ago revenues of $14.74 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Recursion Pharmaceuticals shares have lost about 17.6% since the beginning of the year versus the S&P 500's gain of 6%.

What's Next for Recursion Pharmaceuticals?While Recursion Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Recursion Pharmaceuticals was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.29 on $15.41 million in revenues for the coming quarter and -$1.08 on $67.97 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Stoke Therapeutics, Inc. (STOK - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on May 7.

This company is expected to post quarterly loss of $0.80 per share in its upcoming report, which represents a year-over-year change of -142.1%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Stoke Therapeutics, Inc.'s revenues are expected to be $5.25 million, down 96.7% from the year-ago quarter.

Key Takeaways RXRX posted a Q1 loss of 22 cents per share, beating estimates despite lower revenues.Recursion cut R&D and G&A expenses sharply, driven by lower costs and improved efficiency.RXRX expects cash reserves to support operations into early 2028 under its current plan. Recursion Pharmaceuticals (RXRX - Free Report) reported a loss of 22 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had incurred a loss of 50 cents per share in the year-ago quarter.

In the absence of an approved product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. Total revenues for the quarter were $6 million, declining significantly year over year due to lower revenue recognized from Roche, reflecting the successful completion of certain project phases in the prior-year period. The reported figure missed the Zacks Consensus Estimate of $16 million.

RXRX also recognizes periodic revenues from its ongoing collaboration agreements with Sanofi, Bayer and Merck KGaA, Darmstadt, Germany.

RXRX’s Q1 Results in DetailIn the first quarter of 2026, Research and development (R&D) expenses decreased 32% to $87.9 million. The downtick in R&D expenses can be attributed to lower platform costs due to the timing of Tempus record purchases, along with reduced expenses from improved operating efficiency. The year-ago quarter figure also included a $27.1 million in non-cash expenses related to the use of patient-centric multimodal oncology data in the company’s R&D pipeline.

General and administrative (G&A) expenses were $34.6 million in the reported quarter, down 37% year over year, primarily due to a decrease in salaries and one-time transaction costs incurred in the prior-year quarter. Additionally, Recursion Pharmaceuticals’ cost of revenues in the reported quarter decreased 43% to $12.5 million.

The company had cash, cash equivalents and restricted cash worth $665.2 million as of March 31, 2026, compared to $753.9 million as of Dec. 31, 2025. Recursion Pharmaceuticals expects its existing cash, cash equivalents and restricted cash to fuel operations into early 2028, based on its current business plan.

RXRX shares have plunged 16.2% year to date compared with the industry’s 1.6% decline.

Image Source: Zacks Investment Research

RXRX’s Key Pipeline UpdatesFollowing a strategic reprioritization in 2025, Recursion Pharmaceuticals has shifted its focus and resources to the development of other candidates in its clinical pipeline. Such candidates include REC-4881, which is being developed for familial adenomatous polyposis (FAP) in the phase Ib/II TUPELO study. RXRX has initiated discussions with the FDA to align on the design of a potential registrational study for REC-4881 in FAP, with an update anticipated in the second half of 2026. The company is also continuing efforts to expand the scope of the TUPELO study by including patients aged 18 and older in support of a broader development strategy.

In 2024, Recursion Pharmaceuticals initiated its phase I/II DAHLIA study of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma. RXRX reported preliminary safety and pharmacokinetic data from the DAHLIA study, demonstrating encouraging early clinical progress in targeting cancer vulnerabilities associated with replication stress and DNA repair. Per the early findings, REC-1245 was well tolerated across select solid tumors, with no dose-limiting toxicities observed to date, while pharmacokinetic and pharmacodynamic analyses demonstrated predictable dose-dependent exposure and target engagement as dose escalation continues. Additional data from the phase I portion of the DAHLIA study is expected later in 2026.

Recursion Pharmaceuticals is also developing a few other candidates, like REC-617 (advanced solid tumors), REC-4539 (solid tumors) and REC-3565 (B-cell malignancies), in separate early-stage studies.

In 2025, Recursion Pharmaceuticals acquired Rallybio’s full stake in their joint venture for developing REV102 (now REC-102) and an associated backup molecule for the treatment of hypophosphatasia, a rare and debilitating genetic disorder. REC-102, a potent and selective ENPP1 inhibitor with strong preclinical safety data, is expected to enter phase I studies by late 2026. Its oral formulation offers a major advantage over current enzyme replacement therapies, potentially improving patient adherence and reducing treatment-associated risks.

RXRX’s Zacks Rank & Stocks to ConsiderRecursion Pharmaceuticals currently carries a Zacks Rank #4 (Sell).

Some better-ranked stocks in the biotech sector are Catalyst Pharmaceuticals (CPRX - Free Report) , Immatics (IMTX - Free Report) and Inovio Pharmaceuticals (INO - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Over the past 60 days, estimates for Catalyst Pharmaceuticals’ 2026 EPS have declined from $2.82 to $2.79. CPRX shares have gained 30.8% year to date.

Catalyst Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 35.19%.

Over the past 60 days, estimates for Immatics’ 2026 loss per share have narrowed from $1.61 to $1.49. IMTX shares have gained 9.6% year to date.

Immatics’ earnings beat estimates in three of the trailing four quarters and missed on the remaining occasion, delivering an average negative surprise of 8.06%.

Over the past 60 days, estimates for Inovio Pharmaceuticals’ 2026 loss per share have narrowed from $1.26 to $1.06. INO shares have plunged 28.8% year to date.

Inovio Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 57.94%.

Recursion Pharmaceuticals, Inc. (RXRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Salt Lake City, UT, May 29, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on May 26, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 2,991,840 shares of its class A common stock in the aggregate to 33 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with Recursion, or a subsidiary of Recursion, pursuant to Nasdaq Listing Rule 5635(c)(4).

Each inducement RSU award will vest as to 1/4th of the shares subject to the award on the first quarterly vesting date on or following the one-year anniversary of the vesting commencement date, and as to 1/16th of the shares on each quarterly vesting date thereafter until the inducement RSU award is fully vested, subject to the inducement RSU award recipient’s continued employment through the company vesting dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.

About Recursion

Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, and the Oxford area. Learn more at www.recursion.com, or connect on X and LinkedIn.

Media Contact
[email protected]

Investor Contact
[email protected]

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX - Free Report) . Shares have added about 16.2% in that time frame, outperforming the S&P 500.

But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Recursion Pharmaceuticals due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.

RXRX Q1 Loss Narrower Than Expected, Revenues Decline Y/YRecursionreported a loss of 22 cents per share in the first quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had incurred a loss of 50 cents per share in the year-ago quarter.

In the absence of an approved product, Recursion Pharmaceuticals only recognizes collaboration and grant revenues from its partners. Total revenues for the quarter were $6 million, declining significantly year over year due to lower revenue recognized from Roche, reflecting the successful completion of certain project phases in the prior-year period. The reported figure missed the Zacks Consensus Estimate of $16 million.

RXRX also recognizes periodic revenues from its ongoing collaboration agreements with Sanofi, Bayer and Merck KGaA, Darmstadt, Germany.

RXRX’s Q1 Results in DetailIn the first quarter of 2026, Research and development (R&D) expenses decreased 32% to $87.9 million. The downtick in R&D expenses can be attributed to lower platform costs due to the timing of Tempus record purchases, along with reduced expenses from improved operating efficiency. The year-ago quarter figure also included a $27.1 million in non-cash expenses related to the use of patient-centric multimodal oncology data in the company’s R&D pipeline.

General and administrative (G&A) expenses were $34.6 million in the reported quarter, down 37% year over year, primarily due to a decrease in salaries and one-time transaction costs incurred in the prior-year quarter. Additionally, Recursion Pharmaceuticals’ cost of revenues in the reported quarter decreased 43% to $12.5 million.

The company had cash, cash equivalents and restricted cash worth $665.2 million as of March 31, 2026, compared to $753.9 million as of Dec. 31, 2025. Recursion Pharmaceuticals expects its existing cash, cash equivalents and restricted cash to fuel operations into early 2028, based on its current business plan.

How Have Estimates Been Moving Since Then?Estimates review followed a downward path over the past two months.

The consensus estimate has shifted 12.93% due to these changes.

VGM ScoresCurrently, Recursion Pharmaceuticals has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. However, the stock has a score of F on the value side, putting it in the bottom 20% quintile for this investment strategy.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

Outlook Recursion Pharmaceuticals has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Performance of an Industry PlayerRecursion Pharmaceuticals is part of the Zacks Medical - Biomedical and Genetics industry. Over the past month, Illumina (ILMN - Free Report) , a stock from the same industry, has gained 21.2%. The company reported its results for the quarter ended March 2026 more than a month ago.

Illumina reported revenues of $1.09 billion in the last reported quarter, representing a year-over-year change of +4.8%. EPS of $1.15 for the same period compares with $0.97 a year ago.

Illumina is expected to post earnings of $1.24 per share for the current quarter, representing a year-over-year change of +4.2%. Over the last 30 days, the Zacks Consensus Estimate remained unchanged.

Illumina has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of C.

Recursion Pharmaceuticals (RXRX - Free Report) closed the most recent trading day at $3.06, moving -5.12% from the previous trading session. This change lagged the S&P 500's daily loss of 1.62%. Meanwhile, the Dow experienced a drop of 1.87%, and the technology-dominated Nasdaq saw a decrease of 1.98%.

Shares of the biotechnology company witnessed a gain of 2.22% over the previous month, trailing the performance of the Medical sector with its gain of 5.04%, and outperforming the S&P 500's loss of 0.03%.

The investment community will be closely monitoring the performance of Recursion Pharmaceuticals in its forthcoming earnings report. It is anticipated that the company will report an EPS of -$0.25, marking a 39.02% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $11.99 million, down 37.64% from the year-ago period.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.99 per share and revenue of $54.08 million, indicating changes of +31.25% and -27.59%, respectively, compared to the previous year.

Investors should also take note of any recent adjustments to analyst estimates for Recursion Pharmaceuticals. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.

Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 1.99% upward. Recursion Pharmaceuticals currently has a Zacks Rank of #3 (Hold).

The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 155, which puts it in the bottom 37% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

CIBC Bancorp USA Inc. purchased a new stake in Neogen Corporation (NASDAQ: NEOG) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 5,073,316 shares of the company's stock, valued at approximately $28,969,000. CIBC Bancorp USA Inc. owned approximately 2.33% of Neogen at the

Posted by Defense World Staff on Mar 30th, 2026

SG Americas Securities LLC boosted its position in shares of Neogen Corporation (NASDAQ:NEOG – Free Report) by 929.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,617,597 shares of the company’s stock after acquiring an additional 1,460,488 shares during the period. SG Americas Securities LLC owned 0.74% of Neogen worth $11,307,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of NEOG. GAMMA Investing LLC grew its holdings in Neogen by 34.2% in the fourth quarter. GAMMA Investing LLC now owns 31,347 shares of the company’s stock worth $219,000 after purchasing an additional 7,982 shares during the last quarter. JPMorgan Chase & Co. boosted its position in shares of Neogen by 19.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,680,212 shares of the company’s stock worth $9,594,000 after purchasing an additional 278,886 shares in the last quarter. Tudor Investment Corp ET AL purchased a new position in Neogen during the 3rd quarter worth $62,000. Hudson Bay Capital Management LP acquired a new position in Neogen during the 3rd quarter valued at about $28,550,000. Finally, CIBC Bancorp USA Inc. acquired a new position in Neogen during the 3rd quarter valued at about $28,969,000. 96.73% of the stock is currently owned by institutional investors and hedge funds.

Neogen Stock Performance Shares of NEOG opened at $8.70 on Monday. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.80 and a current ratio of 3.91. The stock has a 50-day moving average of $10.14 and a two-hundred day moving average of $7.77. The stock has a market cap of $1.89 billion, a P/E ratio of -3.14 and a beta of 1.95. Neogen Corporation has a one year low of $3.87 and a one year high of $11.43.

Neogen (NASDAQ:NEOG – Get Free Report) last announced its quarterly earnings data on Thursday, January 8th. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.03. Neogen had a positive return on equity of 2.14% and a negative net margin of 68.47%.The business had revenue of $224.69 million for the quarter, compared to analyst estimates of $208.50 million. During the same period in the prior year, the company earned $0.11 earnings per share. The company’s revenue was down 2.9% on a year-over-year basis. As a group, research analysts predict that Neogen Corporation will post 0.38 EPS for the current year.

Analyst Ratings Changes NEOG has been the subject of several recent analyst reports. Wall Street Zen raised Neogen from a “hold” rating to a “buy” rating in a report on Saturday, February 14th. William Blair restated a “market perform” rating on shares of Neogen in a report on Monday, March 2nd. CJS Securities raised shares of Neogen from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Neogen in a research note on Monday, December 29th. Finally, Guggenheim reissued a “buy” rating and set a $12.00 target price (up from $8.00) on shares of Neogen in a research report on Friday, January 9th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $10.67.

Read Our Latest Report on Neogen

Neogen Company Profile (Free Report)

Neogen Corporation is a global provider of food and animal safety products, offering a broad portfolio of diagnostic and testing solutions. Headquartered in Lansing, Michigan, the company develops and manufactures tests designed to detect foodborne pathogens, allergens and toxins in food, beverage and environmental samples. Since its founding in 1982, Neogen has focused on delivering rapid, accurate and user‐friendly assays to food processors, grain handlers and quality laboratories around the world.

In the food safety arena, Neogen’s product lineup includes immunoassay kits, molecular diagnostics and enrichment media for pathogens such as Salmonella, Listeria and E.

See Also Five stocks we like better than Neogen

Receive News & Ratings for Neogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neogen and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEEastern Bank Sells 9,296 Shares of Uber Technologies, Inc. $UBER

NEXT HEADLINE »USA Financial Formulas Takes Position in Vanguard S&P 500 ETF $VOO

The market expects Neogen (NEOG - Free Report) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended February 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.

The earnings report, which is expected to be released on April 9, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise.

Zacks Consensus EstimateThis maker of medical testing kits is expected to post quarterly earnings of $0.04 per share in its upcoming report, which represents a year-over-year change of -60%.

Revenues are expected to be $204.46 million, down 7.5% from the year-ago quarter.

Estimate Revisions TrendThe consensus EPS estimate for the quarter has been revised 8.33% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts.

Price, Consensus and EPS Surprise

Earnings WhisperEstimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction).

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for Neogen?For Neogen, the Most Accurate Estimate is the same as the Zacks Consensus Estimate, suggesting that there are no recent analyst views which differ from what have been considered to derive the consensus estimate. This has resulted in an Earnings ESP of 0%.

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that Neogen will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?While calculating estimates for a company's future earnings, analysts often consider to what extent it has been able to match past consensus estimates. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that Neogen would post earnings of $0.07 per share when it actually produced earnings of $0.10, delivering a surprise of +42.86%.

Over the last four quarters, the company has beaten consensus EPS estimates just once.

Bottom LineAn earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Neogen doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.

Neogen Corporation (NASDAQ:NEOG) will release earnings for its third quarter before the opening bell on Thursday, April 9.

Analysts expect the Lansing, Michigan-based company to report quarterly earnings of 5 cents per share, down from 10 cents per share in the year-ago period. The consensus estimate for Neogen's quarterly revenue is $204.62 million (it reported $220.98 million last year), according to Benzinga Pro.

On March 2, Neogen announced the sale of Genomics business to Zoetis.

Neogen shares rose 1.6% to close at $9.56 on Monday.

Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.

Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.

Considering buying NEOG stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

LANSING, Mich.--(BUSINESS WIRE)--Neogen Corporation (NASDAQ: NEOG), an innovative leader in food safety solutions, today announced the appointment of Jennifer Evans Stacey as Chief Legal & Compliance Officer and Board Secretary.

Ms. Stacey is an accomplished chief legal and compliance officer and board secretary with extensive experience in the life sciences industry. She has served more than 10 years as a public company chief legal and compliance officer and board secretary, as well as five years as a public company board member. Over her more than 25-year career, she has led legal, compliance, government relations, corporate communications and human resources functions, operating in complex, fast-moving environments.

Most recently, Jennifer served as Chief Legal & Compliance Officer and Secretary at Galera Therapeutics, Inc., a publicly traded biopharmaceutical company focused on oncology. Prior to Galera, she held Chief Legal Officer roles at The Wistar Institute, Antares Pharma, Inc., FXI, Inc., Auxilium Pharmaceuticals, Inc., and Aventis Behring LLC. Jennifer currently serves on the Board of Directors of Context Therapeutics (NASDAQ:CNTX), a publicly traded, clinical stage biopharmaceutical company advancing T cell-engaging bispecific antibodies for solid tumors.

“Jennifer’s experience and life sciences background position her well to support Neogen’s focus on organic growth through innovation and technology licensing, as well as future inorganic growth opportunities,” said Mike Nassif, President and Chief Executive Officer of Neogen. “We’re pleased to welcome her to the leadership team and look forward to her contributions.”

Ms. Stacey holds a Bachelor of Arts degree, magna cum laude, from Princeton University and a Juris Doctor from the University of Pennsylvania Law School.

“Neogen plays an important role in helping to protect the global food supply, and that responsibility requires strong governance and a clear focus on execution,” said Ms. Stacey. “I’m looking forward to partnering with the leadership team to support the business, enhance our compliance framework, and help position the company for sustainable, long-term growth.”

About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.